Drugs that contain Cariprazine Hydrochloride

1. List of Vraylar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943621 ALLERGAN Salts of piperazine compounds as D3/D2 antagonists
Dec, 2028

(5 years from now)

US7737142 ALLERGAN (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47350 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(6 years from now)

USRE49110 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 24, 2022

Market Authorisation Date: 17 September, 2015

Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine

Dosage: CAPSULE;ORAL

How can I launch a generic of VRAYLAR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic